gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
gptkbp:administered_by
|
intravenous infusion
chemotherapy
|
gptkbp:approves
|
gptkb:2012
gptkb:European_Union
gptkb:FDA
gptkb:United_States
|
gptkbp:can_be_combined_with
|
gptkb:trastuzumab
|
gptkbp:chemical_formula
|
C6460 H9932 N1716 O1980 S44
|
gptkbp:clinical_trial
|
gptkb:APHINITY_trial
gptkb:CLEOPATRA_trial
gptkb:NEOSPHERE_trial
Phase III
|
gptkbp:clinical_use
|
adjuvant therapy
neoadjuvant therapy
metastatic breast cancer
|
gptkbp:contraindication
|
pregnancy
lactation
hypersensitivity to pertuzumab
|
gptkbp:developed_by
|
gptkb:Genentech
|
gptkbp:dosing
|
loading dose followed by maintenance dose
|
https://www.w3.org/2000/01/rdf-schema#label
|
pertuzumab
|
gptkbp:indication
|
gptkb:HER2-positive_breast_cancer
|
gptkbp:interacts_with
|
other HER2-targeted therapies
|
gptkbp:invention
|
patented
|
gptkbp:is_monitored_by
|
cardiac function
|
gptkbp:knockouts
|
high
|
gptkbp:marketed_as
|
gptkb:Perjeta
|
gptkbp:mechanism_of_action
|
HER2 receptor blockade
|
gptkbp:pharmacokinetics
|
long half-life
inhibition of HER2 signaling
|
gptkbp:produced_by
|
recombinant DNA technology
|
gptkbp:provides_guidance_on
|
ASCO guidelines
NCCN guidelines
|
gptkbp:research
|
other cancers
|
gptkbp:research_focus
|
combination therapies
biomarker studies
resistance mechanisms
patient selection
|
gptkbp:route_of_administration
|
IV
|
gptkbp:safety_features
|
generally well tolerated
|
gptkbp:service_frequency
|
every 3 weeks
|
gptkbp:shelf_life
|
24 months
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
nausea
diarrhea
peripheral neuropathy
thrombocytopenia
infusion reactions
neutropenia
hypersensitivity reactions
cardiac dysfunction
|
gptkbp:storage
|
refrigerated
|
gptkbp:targets
|
gptkb:HER2
|
gptkbp:treatment
|
with trastuzumab and docetaxel
|
gptkbp:type
|
humanized monoclonal antibody
|
gptkbp:used_for
|
gptkb:Oncology
|
gptkbp:website
|
IV site
|
gptkbp:weight
|
148 k Da
|
gptkbp:bfsParent
|
gptkb:Perjeta
gptkb:Herceptin
|
gptkbp:bfsLayer
|
5
|